1 week ago
Inhibrx Biosciences (INBX) Stock Soars 17% Following Impressive Phase 2 Cancer Data
Inhibrx Biosciences (INBX) stock jumped 17% after Phase 2 data showed INBRX-106 combination therapy doubled response rates in head and neck cancer patients.
The post Inhibrx Biosciences (INBX) Stock Soars 17% Following Impressive Phase 2 Cancer Data appeared first on Blockonomi.
Source: Blockonomi →Related News
- 19 hours ago
Hewlett Packard Enterprise (HPE) Stock Soars to Record Peak as Elliott Expands P...
- 19 hours ago
Norwegian Cruise Line (NCLH) Stock Plummets 9.5% — Company Insiders Buy Big
- 19 hours ago
Dell (DELL) Stock Rockets 16% to All-Time Peak Ahead of May 28 Earnings
- 20 hours ago
BlackBerry (BB) Stock Surges 19% to New 52-Week Peak on Bullish Outlook
- 20 hours ago
Navitas Semiconductor (NVTS) Stock Soars 20% as AI Power Shift Fuels Rally